{"id":5620,"date":"2022-11-30T07:30:00","date_gmt":"2022-11-30T06:30:00","guid":{"rendered":"https:\/\/staybletherapeutics.com\/sv\/cision-feed\/stayble-therapeutics-presenterar-pa-prohearings-kapitalmarknadsdag-den-1-december-2022\/"},"modified":"2022-11-30T07:30:00","modified_gmt":"2022-11-30T06:30:00","slug":"stayble-therapeutics-presenterar-pa-prohearings-kapitalmarknadsdag-den-1-december-2022","status":"publish","type":"cision-feed","link":"https:\/\/staybletherapeutics.com\/sv\/cision-feed\/stayble-therapeutics-presenterar-pa-prohearings-kapitalmarknadsdag-den-1-december-2022\/","title":{"rendered":"Stayble Therapeutics presenterar p\u00e5 ProHearings kapitalmarknadsdag den 1 december 2022"},"content":{"rendered":"

Presentation och fr\u00e5gestund s\u00e4nds live via l\u00e4nk p\u00e5 <\/span>www.prohearings.com<\/u><\/span><\/a>, d\u00e4r det \u00e4ven g\u00e5r att anm\u00e4la personligt deltagande p\u00e5 eventet. Det g\u00e5r att skicka in fr\u00e5gor till moderatorn genom att maila info@prohearings.com. Efter evenemanget kommer presentationen finnas tillg\u00e4nglig p\u00e5 v\u00e5r hemsida <\/span>https:\/\/staybletherapeutics.com\/sv\/<\/u><\/span><\/a>.<\/span><\/p>\n

 <\/span><\/p>\n

N\u00e4r<\/strong><\/span>: Staybles presentation b\u00f6rjar 11:00.<\/span><\/p>\n

Var<\/strong><\/span>: Scandic Anglais, Stureplan, Stockholm och live via <\/span>www.prohearings.com<\/u><\/span><\/a>. <\/u><\/span> <\/span> <\/span><\/p>\n

 <\/span><\/p>\n

F\u00f6r mer information<\/span><\/h2>\n

Andreas Gerward, VD Stayble Therapeutics AB<\/span><\/p>\n

E-post: andreas.gerward@stayble.se <\/span><\/p>\n

Telefon: +46 730 808<\/span> <\/span>397<\/span><\/p>\n

 <\/span><\/p>\n

Om Stayble Therapeutics AB<\/span><\/h2>\n

Stayble \u00e4r ett kliniskt l\u00e4kemedelsbolag som utvecklar injektionsbehandlingen STA363 mot kronisk diskrelaterad ryggsm\u00e4rta. Behandlingen riktar sig till patienter som inte blir hj\u00e4lpta av sjukgymnastik och sm\u00e4rtstillande preparat. Injektionen ges vid ett tillf\u00e4lle och effekten ber\u00e4knas kvarst\u00e5 hela livet och kr\u00e4va minimal rehabilitering. Bolaget har nu fokus p\u00e5 den fortsatta kliniska utvecklingen och genomf\u00f6r just nu en klinisk fas 2b-studie. Staybles vision \u00e4r att utveckla STA363 som ny standardbehandling f\u00f6r patienter som lider av kronisk diskrelaterad ryggsm\u00e4rta. <\/span><\/p>\n

 <\/span><\/p>\n

Bolagets Certified Adviser \u00e4r Svensk Kapitalmarknadsgranskning AB som n\u00e5s p\u00e5 telefonnummer +46 11 32 30 732 eller e-post <\/span>ca@skmg.se<\/u><\/span><\/a> <\/span><\/p>\n

 <\/span><\/p>\n","protected":false},"excerpt":{"rendered":"

Torsdag den 1 december deltar Stayble Therapeutics AB (\u201dStayble\u201d eller \u201dBolaget\u201d) p\u00e5 ProHearings investerarevent. Bolagets VD, Andreas Gerward, kommer ge en investerarpresentation och svarar p\u00e5 fr\u00e5gor i en modererad fr\u00e5gestund efter presentationen.<\/p>\n","protected":false},"author":0,"featured_media":0,"comment_status":"closed","ping_status":"closed","template":"","meta":[],"_links":{"self":[{"href":"https:\/\/staybletherapeutics.com\/sv\/wp-json\/wp\/v2\/cision-feed\/5620"}],"collection":[{"href":"https:\/\/staybletherapeutics.com\/sv\/wp-json\/wp\/v2\/cision-feed"}],"about":[{"href":"https:\/\/staybletherapeutics.com\/sv\/wp-json\/wp\/v2\/types\/cision-feed"}],"replies":[{"embeddable":true,"href":"https:\/\/staybletherapeutics.com\/sv\/wp-json\/wp\/v2\/comments?post=5620"}],"version-history":[{"count":0,"href":"https:\/\/staybletherapeutics.com\/sv\/wp-json\/wp\/v2\/cision-feed\/5620\/revisions"}],"wp:attachment":[{"href":"https:\/\/staybletherapeutics.com\/sv\/wp-json\/wp\/v2\/media?parent=5620"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}